Celebrating Innovation: Prix Galien Photo Gallery
Pharmaceutical Executive
Photos from the awards ceremony of the first US Prix Galien, September 25, 2007 in New York City.
The Prix Galien Awards were established more than 30 years ago in France to honor research innovation within the pharmaceutical industry. Since their creation, the awards have expanded to other countries around the globe. This year marked the first time the Prix Galien Awards honored American innovation. The black-tie event—held on Sept. 25, 2007, at New York City's swank Cipriani—was truly a star-studded affair, presided over by television personality Charlie Rose and featuring a special appearance by author and Nobel Peace Prize laureate Elie Wiesel. Medals were awarded by an esteemed panel of judges, including the six Nobel laureates in attendance. Pfizer's Chantix and Merck's Januvia took home awards for best pharmaceutical product, and Abbott Labs' Humira and Merck's Gardasil won in the biotech class—but a good time was had by all.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
